CoChat

A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial

Dakwar, Elias, Levin, Frances, Hart, Carl L., Basaraba, Cale, Choi, Jean, Pavlicova, Martina, Nunes, Edward V. · 2020 · American Journal of Psychiatry

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Pharmacotherapy and behavioral treatments for alcohol use disorder are limited in their effectiveness, and new treatments with innovative mechanisms would be valuable. In this pilot study, the authors tested whether a single subanesthetic infusion of ketamine administered to adults with alcohol dependence and engaged in motivational enhancement therapy affects drinking outcomes. METHODS: Participants were randomly assigned to a 52-minute intravenous administration of ketamine (0.71 mg/kg, N=17) or the active control midazolam (0.025 mg/kg, N=23), provided during the second week of a 5-week outpatient regimen of motivational enhancement therapy. Alcohol use following the infusion was assessed with timeline followback method, with abstinence confirmed by urine ethyl glucuronide testing. A longitudinal logistic mixed-effects model was used to model daily abstinence from alcohol over the 21 days after ketamine infusion. RESULTS: Participants (N=40) were mostly middle-aged (mean age=53 years [SD=9.8]), predominantly white (70.3%), and largely employed (71.8%) and consumed an average of five drinks per day prior to entering the study. Ketamine significantly increased the likelihood of abstinence, delayed the time to relapse, and reduced the likelihood of heavy drinking days compared with midazolam. Infusions were well tolerated, with no participants removed from the study as a result of adverse events. CONCLUSIONS: A single ketamine infusion was found to improve measures of drinking in persons with alcohol dependence engaged in motivational enhancement therapy. These preliminary data suggest new directions in integrated pharmacotherapy-behavioral treatments for alcohol use disorder. Further research is needed to replicate these promising results in a larger sample.

Overview

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2019.19070684

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 30 references

Research works printed but not linked: 2

  1. Smedslund G, 2011, Cochrane Database Syst Rev, CD008063
  2. Niciu MJ, 2014, Int J Neuropsychopharmacol, 18, 1

Cited by

See all 202

Metadata

Authors
Dakwar, E., Levin, F., Hart, C. L., Basaraba, C., Choi, J., Pavlicova, M., & Nunes, E. V.
Affiliations
  • Columbia University Irving Medical Center (US)
  • New York State Psychiatric Institute, Columbia University Medical Center, New York (Dakwar, Levin, Hart, Nunes); the Department of Psychology, Columbia University, New York (Hart); the Division of Mental Health Data Science, New York State Psychiatric Institute, New York (Basaraba, Choi); the Department of Biostatistics, Mailman School of Public Health, Columbia University, New York (Pavlicova).
Venue
American Journal of Psychiatry
Published
2020-02-01
Volume
177
Issue
2
Pages
125-133
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W2991597523
Cited by
183
References
30
Citations by year
2026: 22 · 2025: 40 · 2024: 38 · 2023: 23 · 2022: 28 · 2021: 17 · 2020: 14
FWCI
11.41
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
ketamine, motivational enhancement therapy, alcoholism, alcohol abstinence, relapse, heavy drinking
MeSH terms
Alcoholism, Combined Modality Therapy, Double-Blind Method, Female, Humans, Infusions, Intravenous, Ketamine, Male, Midazolam, Middle Aged, Pilot Projects, Psychotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial. https://app.cochat.ai/papers/10.1176/appi.ajp.2019.19070684
The paper
Dakwar, E., Levin, F., Hart, C. L., Basaraba, C., Choi, J., Pavlicova, M., & Nunes, E. V. (2020). A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2019.19070684

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.